Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | DREAMM-3: belantamab mafodotin vs pom/dex for R/R myeloma

Katja Weisel • 31 May 2020
EHA 2020
Multiple Myeloma Antibodies Belantamab mafodotin Pomalidomide
DREAMM-3 GMMG-CONCEPT

Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses DREAMM-3, a Phase III, open-label, randomized study of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone (pom/dex) in relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Katja Weisel

1:02
DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myeloma
Katja Weisel • 3 Jun 2023
1:28
Ocular adverse events with ADCs
Katja Weisel • 10 Sep 2021
3:02
ADCs for the treatment of myeloma
Katja Weisel • 10 Sep 2021
1:43
MRD: from clinical trials to clinical practice
Katja Weisel • 10 Sep 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals